6-Jul-2026
At a glance: stocks gapping up premarket
Seeking Alpha News (Tue, 7-Jul 7:35 AM ET)
TipRanks (Tue, 7-Jul 6:01 AM ET)
Biggest stock movers Tuesday: CRNX, RIVN, and more
Seeking Alpha News (Tue, 7-Jul 5:01 AM ET)
Why Is Crinetics Stock (CRNX) Surging Nearly 100% in Pre-Market Today, 7/7/26? Analysts React
TipRanks (Tue, 7-Jul 4:58 AM ET)
PRNewswire (Mon, 6-Jul 7:41 PM ET)
Business Wire (Mon, 6-Jul 5:53 PM ET)
Vertex to Acquire Crinetics in $10 Billion Merger
TipRanks (Mon, 6-Jul 5:50 PM ET)
M&A News: Vertex Stock (VRTX) Slips After Announcing the $10B Crinetics Acquisition
TipRanks (Mon, 6-Jul 5:23 PM ET)
M&A News: Vertex Stock (VRTX) Slips After Announcing $10B Crinetics Acquisition
TipRanks (Mon, 6-Jul 5:23 PM ET)
Vertex to acquire Crinetics Pharmaceuticals in $10B deal
Seeking Alpha News (Mon, 6-Jul 4:21 PM ET)
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Crinetics Pharmaceuticals trades on the NASDAQ stock market under the symbol CRNX.
As of July 6, 2026, CRNX stock price declined to $42.03 with 1,703,359 million shares trading.
CRNX has a beta of 1.07, meaning it tends to be more sensitive to market movements. CRNX has a correlation of 0.05 to the broad based SPY ETF.
CRNX has a market cap of $4.43 billion. This is considered a Mid Cap stock.
Last quarter Crinetics Pharmaceuticals reported $10 million in Revenue and -$1.23 earnings per share. This beat revenue expectation by $2 million and met earnings estimates .
In the last 3 years, CRNX traded as high as $62.53 and as low as $15.76.
The top ETF exchange traded funds that CRNX belongs to (by Net Assets): VTI, IWM, VB, VBK, VXF.
CRNX has outperformed the market in the last year with a price return of +41.0% while the SPY ETF gained +21.3%. However, in the short term, CRNX had mixed performance relative to the market. It has underperformed in the last 3 months, returning +11.5% vs +14.3% return in SPY. But in the last 2 weeks, CRNX shares have fared better than the market returning +18.8% compared to SPY +0.9%.
CRNX support price is $40.80 and resistance is $43.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRNX shares will trade within this expected range on the day.
